EpiPen. HIV Drugs. Hep C Treatment. Insulin.

The list of drugs that have grabbed headlines for dizzyingly high prices are just the tip of the iceberg. Pharmaceutical companies’ habit of pushing the limits on drug prices is costing states like California billions and driving up the cost of healthcare.

Enough is enough. It’s time for solutions.

California Takes On Out-of-Control Prescription Drug Pricing

The pharmaceutical industry spent years stalling transparency legislation in the state legislature but, California families made progress this year with the passage of SB 17. There’s more to be done, but this landmark legislation will pave the way for more sustainable, affordable prescription drug prices.

Stay Informed

Stay up to date on the fight against runaway prescription drug prices.
17 hours ago
Why is #BigPharma trying to stop #SB17? Because the industry "really, really doesn’t want you to know that it’s ripping you off with frequent and questionable price increases for prescription meds." More from @Davidlaz: https://t.co/FGSix0h6L3
1 day ago
Annual prescription drug spending by @CalPERS has increased by more than $600 billion since 2011. Check out @pbartolone’s latest piece for more on how the Rx price crisis is impacting CA’s public employee health system: https://t.co/LpefnMi7UB
3 days ago
Avondale Pharmaceuticals recently hiked the price of Niacor, a prescription-only version of niacin, by more than 800 percent, raising a bottle of 100 tablets from $32.46 to $295, per the @FinancialTimes https://t.co/SnTBfCUEip
3 days ago
New @PwC report on 2018 health care industry challenges cites transparency as key issue, refers to #SB17 as the “strongest pricing transparency legislation yet passed at the state level… widely supported by consumer groups, business interests and payers.” https://t.co/oU1FVOClaF https://t.co/fCt1C3mB29

Transparency in Drug Pricing

Health coverage protects us from most of Big Pharma’s price gouging, but drugs with six-figure price tags drive up the cost of care for everyone.
In 2017, California passed SB 17 to bring pharmaceutical companies’ pricing tactics out of the dark and begin to address the growing affordability crisis. The bill, which will serve as a model for the nationwide push to address rising prescription drug prices, came on the tails of truly outrageous price hikes, like Mylan’s decision to needlessly up the price of EpiPens by nearly 500 percent and Gilead Sciences’ pricing of a lifesaving treatment at $1,000 per pill. While examples like these are widely known, the pharmaceutical industry has been quietly upping the price of old and new drugs alike. This destructive practice has led prescription drug prices to become the fastest growing portion of the health care dollar.

SB 17 Will:

Give A Heads
Up On
Price Hikes

Price Hike Alerts - Icon
Drug companies will give payers notice of major price increases for the most expensive drugs

Help Plan

Planning for Increases - Icon
Payers can plan ahead for significant price increases on medications

Provide Data
To Inform

Informed Solutions - Icon
Lawmakers can review historical trends on drug costs to inform solutions


Public Accountability - Icon
Public will have access to basic information on what drives price hikes and drug spending